Dược phẩm

TRA

Traphaco

80,000
-0.37%
Mkt Cap 414.5B
Data as of 2026-06-05 · Source: public Vietnamese market feeds

TRA is a Vietnam-listed stock for Traphaco in the Dược phẩm sector. The latest tracked close is 80,000 VND, -0.37% on the session. Aveluro has analyzed 4 Vietnamese financial news articles mentioning TRA, with neutral as the dominant sentiment; the latest catalyst is sector sentiment: Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT.

What matters now

Latest price
80,000 VND · -0.37%
Dominant Sentiment
Neutral · 4 Articles Analyzed
Latest catalyst
sector sentiment
Liquidity
Low
Data as of
2026-06-05

Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT

Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.

6.2
Hold
Sentiment
+0.00
Impact
0.50
Momentum
+0.00
Fundamentals
+0.00
Volume
0.00

Want to trade TRA? Compare brokers for Vietnam stocks.

Foreign investors need a broker that can handle Vietnam market access, settlement, custody, and foreign ownership limits.

Compare brokers

Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.

Price Chart
Liquidity
10-Session Avg Vol
7.5K
Today's Volume
2.8K
vs Avg
0.37×
Market Cap
₫414.5B
Liquidity
Low

Low liquidity — thin average daily volume may result in wider spreads and price impact on larger orders.

News Sentiment
Articles Analyzed
4
Dominant Sentiment
Neutral
Neutral 3
Positive 1
Recent News
Full Analysis sector sentiment May 13, 2026
Foreign Ownership Dominates Vietnam's Top Pharma Stocks: DHG, IMP, DHT

Vietnam's top three pharma companies by market cap—DHG, IMP, and DHT—are now under foreign control or significant influence, with Taisho, Livzon, and ASKA as key shareholders. The sector is projected to double from $8-9 billion to $16 billion by 2032, driving M&A interest.

4 Neutral
Read full analysis →
Apr 10, 2026
4 Positive
Apr 10, 2026
7 Neutral
Full Analysis m a announcement
Chinese Livzon Acquires 67.87% of Imexpharm (IMP) for VND 6,000B in Landmark Pharma M&A

IMP is now majority-owned by China's Livzon after a VND 6,000B deal for 67.87% of shares. The acquisition gives Livzon control of IMP's 12 EU-GMP production lines, a rare asset in Vietnam. The deal underscores a broader trend of foreign domination among top Vietnamese pharma firms, including DHG (Taisho), DMC (Abbott), and DHT (ASKA).

8 Neutral
Read full analysis →
Related Stocks — Dược phẩm
DBD Dược - Trang thiết bị y tế Bình Định stock analysis DCL Dược phẩm Cửu Long stock analysis DHG Dược Hậu Giang stock analysis DMC Xuất nhập khẩu Y tế Domesco stock analysis IMP Dược phẩm Imexpharm stock analysis LDP Dược Lâm Đồng - Ladophar stock analysis MED Dược Trung ương Mediplantex stock analysis
Stock Analysis
TRA stock news Vietnam Dashboard Vietnam stocks for foreigners Foreign ownership limits

Information provided for educational purposes only. Past performance does not guarantee future results. Data sourced from public Vietnamese market feeds.

Last updated: 2026-06-05T21:19:04Z.

About · Methodology · Privacy